Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617
Tóm tắt
To quantitatively predict the impact of cardiopulmonary dose on overall survival (OS) after radiotherapy for locally advanced non–small cell lung cancer.
We used the NRG Oncology/RTOG 0617 dataset. The model building procedure was preregistered on a public website. Patients were split between a training and a set-aside validation subset (N = 306/131). The 191 candidate variables covered disease, patient, treatment, and dose-volume characteristics from multiple cardiopulmonary substructures (atria, lung, pericardium, and ventricles), including the minimum dose to the hottest x% volume (Dx%[Gy]), mean dose of the hottest x% (MOHx%[Gy]), and minimum, mean (Mean[Gy]), and maximum dose. The model building was based on Cox regression and given 191 candidate variables; a Bonferroni-corrected P value threshold of 0.0003 was used to identify predictors. To reduce overreliance on the most highly correlated variables, stepwise multivariable analysis (MVA) was repeated on 1000 bootstrapped replicates. Multivariate sets selected in ≥10% of replicates were fit to the training subset and then averaged to generate a final model. In the validation subset, discrimination was assessed using Harrell c-index, and calibration was tested using risk group stratification.
Four MVA models were identified on bootstrap. The averaged model included atria D45%[Gy], lung Mean[Gy], pericardium MOH55%[Gy], and ventricles MOH5%[Gy]. This model had excellent performance predicting OS in the validation subset (c = 0.89).
The risk of death due to cardiopulmonary irradiation was accurately modeled, as demonstrated by predictions on the validation subset, and provides guidance on the delivery of safe thoracic radiotherapy.
Từ khóa
Tài liệu tham khảo
Bradley, 2015, Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0
Antonia, 2017, Durvulumab after chemoradiotherapy in stage III non-small cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937
Tucker, 2016, Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation, Radiother Oncol, 119, 495, 10.1016/j.radonc.2016.04.025
Stam, 2017, Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy, Radiother Oncol, 125, 62, 10.1016/j.radonc.2017.09.004
McWilliam, 2017, Radiation dose to heart base linked with poorer survival in lung cancer patients, Eur J Cancer, 85, 106, 10.1016/j.ejca.2017.07.053
Vivekanden, 2017, The impact of cardiac radiation dosimetry on survival after radiation therapy for non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 99, 51, 10.1016/j.ijrobp.2017.04.026
Contreras, 2018, Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer, Radiother Oncol, 128, 498, 10.1016/j.radonc.2018.05.017
Speirs, 2017, Heart dose in an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer, J Thorac Oncol, 12, 293, 10.1016/j.jtho.2016.09.134
Deasy, 2010, Improving normal tissue complication probability models: the need to adopt a “data-pooling” culture, Int J Radiat Oncol Biol Phys, 76, 151, 10.1016/j.ijrobp.2009.06.094
Thor, The role of heart-related dose-volume metrics on overall survival in the RTOG 0617 clinical trial, 10.17605/OSF.IO/HZSVA
Wheatley, 2014, Defining a novel cardiac contouring atlas for NSCLC using cadaveric anatomy, Int J Radiat Oncol Biol Phys, 90, 658, 10.1016/j.ijrobp.2014.05.1943
El Naqa, 2006, Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships, Phys Med Biol, 51, 5719, 10.1088/0031-9155/51/22/001
Mayo, 2018, American Association of Physicists in Medicine Task Group 263: standardizing nomenclatures in radiation oncology, Int J Radiat Oncol Biol Phys, 100, 1057, 10.1016/j.ijrobp.2017.12.013
Royston, 2013, External validation of a Cox prognostic model: principles and methods, BMC Med Res Methodol, 33, 1
Moons, 2015, Transparent reporting of a multivariate prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration, Ann Intern Med, 162, 1, 10.7326/M14-0698
Zhang, 1999, Developing robust non-linear models through bootstrap aggregated neural networks, Neurocomputing, 25, 93, 10.1016/S0925-2312(99)00054-5
Bradley, 2020, Long-term of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small cell lung cancer, J Clin Oncol, 38, 706, 10.1200/JCO.19.01162
Darby, 2013, Risk of ischemic heart disease in women after radiotherapy for breast cancer, N Engl J Med, 368, 987, 10.1056/NEJMoa1209825
van Nimwegen, 2016, Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma, J Clin Oncol, 34, 235, 10.1200/JCO.2015.63.4444
Dess, 2017, Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non- small-cell lung cancer, J Clin Oncol, 35, 1395, 10.1200/JCO.2016.71.6142
Wang, 2017, Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy, J Clin Oncol, 35, 1387, 10.1200/JCO.2016.70.0229
Thor, 2020, Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to a treatment-related immunosuppression, Radiother Oncol, 143, 51, 10.1016/j.radonc.2019.07.016